Records containing: Ovarian Cancer
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2023-03-07MELISA Trial: Mapping sEntinel Lymph Node in Initial StAges of Ovarian Cancer
-
CLINICAL_TRIALS study record update · 2023-03-01Effects of Cytotoxic Chemotherapy and PARP Inhibition on the Genomic Contexture of Ovarian Cancer
-
CLINICAL_TRIALS study record update · 2023-02-28Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
-
CLINICAL_TRIALS study record update · 2023-02-23Guangzhou Women's Health Cohort Study (GWHCS)
-
CLINICAL_TRIALS study record update · 2023-02-22Open Label Phase II Clinical Trial of Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GreKo III Study
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2023-02-17The Efficacy of Hyperthermic Intraperitoneal Chemotherapy to Ovarian Cancer Patients With Homologous Recombination Repair Defect and Residual: a Prospective Cohort Study
-
CLINICAL_TRIALS study record update · 2023-02-17A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
-
CLINICAL_TRIALS study record update · 2023-02-13A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination With Pegylated Liposomal Doxorubicin (PLD) or Paclitaxel (Pac) in Patients With Platinum-resistant Recurrent Ovarian Cancer
-
CLINICAL_TRIALS study record update · 2023-02-06Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients
-
CLINICAL_TRIALS study record update · 2023-02-03Development of a Decision Aid to Facilitate Ovarian Cancer Patient's Choices Regarding Biomarker CA125
-
CLINICAL_TRIALS study record update · 2023-01-31A Phase 2, Multicenter, Open-Label Basket Study of Navicixizumab Monotherapy or in Combination With Paclitaxel or Irinotecan in Patients With Select Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2023-01-30Phase II Trial of Maintenance Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer
-
CLINICAL_TRIALS study record update · 2023-01-26Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer: Prospective Study of Pharmacokinetics Patterns and Underlying Biology
-
CLINICAL_TRIALS study record update · 2023-01-26Systematic Nurse-Led Consultations Based on Electronic Patient-Reported Outcome Among Women With Gynecological Cancer During Chemotherapy (The CONNECT Study)
-
CLINICAL_TRIALS study record update · 2023-01-25Phenotypic Spectrum of Circulating Tumor Cell Populations as Markers of Liquid Biopsy in Tumors of the Female Reproductive System
-
CLINICAL_TRIALS study record update · 2023-01-23A Prospective Study of Early Detection of Ovarian Cancer Using Plasma Cell-free DNA Fragmentomics
-
CLINICAL_TRIALS study record update · 2023-01-23A Retrospective Study of Early Detection of Ovarian Cancer Using Plasma Cell-free DNA Fragmentomics
-
CLINICAL_TRIALS study record update · 2023-01-18A Phase 1, Open Label, Multi-Center, Single and Multiple Dose, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S in Previously Treated Patients With Advanced or Metastatic Cancers With High LAT1 Signatures, and in Patients With Relapsed or Refractory Grade 4 Astrocytoma
-
CLINICAL_TRIALS study record update · 2023-01-05Phase 1b & 2 Study With GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer (VIRO-15)
-
CLINICAL_TRIALS study record update · 2023-01-05First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors
-
CLINICAL_TRIALS study record update · 2023-01-03An Open Label, Single-center, Phase 1 Study to Evaluate the Safety of Cancer Immunotherapy With Autologous Dendritic Cells in Patients With Advanced or Recurrent Epithelial Ovarian Cancer
-
CLINICAL_TRIALS study record update · 2023-01-03Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy
-
CLINICAL_TRIALS study record update · 2022-12-30A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
-
CLINICAL_TRIALS study record update · 2022-12-30Randomized Phase II Study of 3 vs 6 Courses of Neoadjuvant Carboplatin-paclitaxel Chemotherapy in Stage IIIC or IV Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma
-
CLINICAL_TRIALS study record update · 2022-12-29Prospective Pilot Study for the Evaluation of the Predictive Value of Blood Levels of Angiopoietin 1 (ANG1) and Endothelial Internal Tunica Cell Kinase 2 (TiE2) in Patients With Ovarian Cancer Treated With Chemotherapy Associated to bevAcizumab